All In Biotech

Drug Trial Radar · NCT02865538

Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms

Evaluation of the Pharmacokinetics and Safety of NT-814 in Post-Menopausal Women With Vasomotor Symptoms

Last checked: Nov 20, 2026Latest source record: Feb 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

76

Actual

Start

Aug 1, 2016

Primary completion

Mar 28, 2017

Study completion Mar 28, 2017

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
Collaborators
Nerre Therapeutics Ltd.
First posted
Aug 12, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 45 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, double-blind, randomized, placebo-controlled multiple ascending dose study in post-menopausal women with vasomotor symptoms. Single ascending doses of NT-814 will be investigated in 4 cohorts. Each cohort will comprise of 20 subjects. Subjects will be dosed for 14 days.

Conditions

  • Post-menopausal Vasomotor Symptoms

Interventions

  • BAY3427080Drug

  • Placebo (for BAY3427080)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Concentration (Cmax) of BAY3427080Time frame: On Day 1, Day 7 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0 hours) and on Day 14 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0, 48.0, 72.0 hours)
  2. Time to Reach Maximum Observed Drug Concentration in Plasma (Tmax) of BAY3427080Time frame: On Day 1, Day 7 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0 hours) and on Day 14 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0, 48.0, 72.0 hours)
  3. Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of BAY3427080Time frame: Day 1 (pre-dose and post-dose (0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 8.0, 12.0 and 24.0 hours)
  4. Area Under the Concentration-time Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-τ) of BAY3427080Time frame: On Day 1, Day 7 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0 hours) and on Day 14 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0, 48.0, 72.0 hours)
  5. Terminal Elimination Half-life (t½) of BAY3427080Time frame: On Day 1, Day 7 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0 hours) and on Day 14 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0, 48.0, 72.0 hours)
  6. Apparent Clearance (CL/F) of BAY3427080Time frame: On Day 1, Day 7 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0 hours) and on Day 14 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0, 48.0, 72.0 hours)
  7. Number of Participants With Clinically Significant Abnormalities Detected Upon Physical Examination.Time frame: At day 14
  8. Number of Participants With Clinically Significant Abnormalities on the 12-lead ECGsTime frame: At day 14
  9. Number of Participants With Arrhythmias as Assessed by Continuous Holter Monitoring.Time frame: Baseline (day -1) and day 14
  10. Change From Baseline at Day 14 in Vital Signs: Diastolic Blood Pressure (Standing)Time frame: Baseline and day 14
  11. Change From Baseline at Day 14 in Vital Signs: Diastolic Blood Pressure (Sitting)Time frame: Baseline and day 14
  12. Change From Baseline at Day 14 in Vital Signs: Systolic Blood Pressure (Standing)Time frame: Baseline and day 14
  13. Change From Baseline at Day 14 in Vital Signs: Systolic Blood Pressure (Sitting)Time frame: Baseline and day 14
  14. Change From Baseline at Day 14 in Vital Signs: Pulse RateTime frame: Baseline and day 14
  15. Change From Baseline at Day 14 in Vital Signs: Respiratory RateTime frame: Baseline and day 14
  16. Change From Baseline at Day 14 in Vital Signs: Oxygen SaturationTime frame: Baseline and day 14
  17. Change From Baseline at Day 14 in Vital Signs: Oral Body TemperatureTime frame: Baseline and day 14
  18. Change From Baseline at Day 14 in Vital Signs: WeightTime frame: Baseline and day 14
  19. Change From Baseline at Day 15 for Laboratory Hormones Results : Adrenocorticotropic Hormone (ADTH) and Estradiol.Time frame: Baseline and day 15
  20. Change From Baseline at Day 15 for Laboratory Hormones Results: Follicle Stimulating HormoneTime frame: Baseline and day 15
  21. Change From Baseline at Day 15 for Laboratory Hormones Results : Triiodothyronine UptakeTime frame: Baseline and day 15
  22. Change From Baseline at Day 15 for Laboratory Hormones Results: ThyrotropinTime frame: Baseline and day 15
  23. Change From Baseline at Day 15 for Laboratory Hormones Results : Cortisol, Testosterone, Thyroxine and TriiodothyronineTime frame: Baseline and day 15
  24. Change From Baseline at Day 14 for Clinical Laboratory Parameters LIPIDS : Cholesterol, Triglycerides, HDL Cholesterol and LDL Cholesterol.Time frame: Baseline and day 14
  25. Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils and Immature Granulocytes.Time frame: Baseline and day 14
  26. Change From Baseline at Day 14 for Clinical Laboratory Parameters HEMATOLOGY: Leukocytes, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, Immature Granulocytes and Platelets.Time frame: Baseline and day 14
  27. Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Hemoglobin and Erythrocytes Mean Corpuscular Hemoglobin ConcentrationTime frame: Baseline and day 14
  28. Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: ErythrocytesTime frame: Baseline and day 14
  29. Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Erythrocytes Mean Corpuscular Volume and Mean Platelet Volume.Time frame: Baseline and day 14
  30. Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Erythrocytes Mean Corpuscular HemoglobinTime frame: Baseline and day 14
  31. Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Erythrocytes Distribution Width.Time frame: Baseline and day 14
  32. Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Hematocrit.Time frame: Baseline and day 14
  33. Change From Baseline at Day 14 for Laboratory Parameters CHEMISTRY: Protein and Albumin.Time frame: Baseline and day 14
  34. Change From Baseline at Day 14 for Laboratory Parameters CHEMISTRY: Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, Gamma Glutamyl Transferase and Creatine KinaseTime frame: Baseline and day 14
  35. Change From Baseline at Day 14 for Laboratory Parameters CHEMISTRY: Urate, Bilirubin and Creatinine.Time frame: Baseline and day 14
  36. Change From Baseline at Day 14 for Clinical Laboratory Parameters CHEMISTRY: Sodium, Potassium, Chloride, Bicarbonate, Calcium, Phosphate, Glucose, Magnesium and Urea Nitrogen.Time frame: Baseline and day 14
  37. Laboratory Parameters CHEMISTRY: Glomerular Filtration Rate African at BaselineTime frame: At Baseline
  38. Laboratory Parameters CHEMISTRY: Glomerular Filtration Rate Caucasian at BaselineTime frame: At Baseline
  39. Change From Baseline at Day 14 for COAGULATION: Prothrombin International Normalized Ratio (INR)Time frame: Baseline and day 14
  40. Change From Baseline at Day 14 for COAGULATION: Prothrombin Time and Activated Partial Thromboplastin TimeTime frame: Baseline and day 14
  41. Heart Rate (HR) - Change From Baseline (Day -1) at Day 14Time frame: Baseline (day -1) and day 14
  42. Mean PR Interval - Change From Baseline (Day -1) at Day 14Time frame: Baseline (day -1) and day 14
  43. Mean QRS Duration - Change From Baseline (Day -1) at Day 14Time frame: Baseline (day -1) and day 14
  44. Mean QT Interval - Change From Baseline (Day -1) at Day 14Time frame: Baseline (day -1) and day 14
  45. Mean QTcF Interval (Fridericia's Correction Formula, QTcF) - Change From Baseline (Day -1) at Day 14Time frame: Baseline (day -1) and day 14
  46. Mean QTcB Interval (Bazett's Correction Formula, QTcB) - Change From Baseline (Day -1) at Day 14Time frame: Baseline (day -1) and day 14
  47. Nature and Severity of Adverse Events (AEs) up to Day 21Time frame: On or after first drug administration up to end of study (Day 21).
  48. Withdrawals Due to AEs up to Day 21Time frame: On or after first drug administration up to end of study (Day 21)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Avail Clinical Research

    DeLand, Florida

  • QPS/MRA (Miami Clinical Research)

    Miami, Florida

  • ICON Clinical Research Unit

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.